Parent-Rated Improvement Is Not Enough to Establish Clinical Scalability

Why It Matters

Relying on parent‑reported outcomes without objective, long‑term data may overstate efficacy, limiting the ability to adopt a‑cTBS widely for autism treatment.

Key Takeaways

• Trial included children with autism and co‑occurring intellectual disability.
• Primary outcome relied on caregiver‑rated SRS‑2, not real‑world function.
• Adverse events like scalp discomfort may have biased caregiver impressions.
• One‑month follow‑up too short to assess durable clinical benefit.
• Future trials need objective, blinded outcomes and longer monitoring.

Pulse Analysis

Accelerated continuous theta burst stimulation (a‑cTBS) represents a cutting‑edge neuromodulation approach that promises rapid cortical plasticity. The recent multicentre BMJ trial enrolled over 200 children, many under eight years old and some with intellectual disability, delivering ten daily sessions over five days. While the protocol showcases the feasibility of intensive treatment in a pediatric setting, the primary efficacy signal hinged on the Social Responsiveness Scale, a caregiver‑reported questionnaire that captures perceived social traits rather than concrete functional gains.

Critics highlight that the modest SRS‑2 improvement barely exceeded the authors’ post‑hoc minimal clinically important difference, and no parallel gains emerged on the Vineland‑3 adaptive‑behaviour scales. Moreover, the active group experienced higher rates of restlessness and scalp discomfort, factors that can subtly influence caregiver perception and inflate reported benefits. Without prospectively measured expectancy or blinded clinician assessments, the risk of placebo‑driven bias remains significant, especially when the primary endpoint is subjective.

For a‑cTBS to transition from experimental to scalable therapy, future research must incorporate objective outcome metrics—such as blinded observational ratings, neurophysiological markers, or school‑based performance data—and extend follow‑up to six months or beyond. Evaluating treatment burden, safety in younger cohorts, and equitable access will determine whether the modest statistical gains translate into meaningful, lasting improvements for children with autism. Until such rigorous evidence accumulates, clinicians should view a‑cTBS as an investigational tool rather than a standard of care.